Testimony, Comments, & Letters

;

Comments on drug pricing transparency interim final rule [CMS-9905-IFC]

Jan 21, 2022

We are pleased that the Biden administration is moving forward with the requirement that insurance plans must report on various data points associated with prescription drug spending. We believe with this greater understanding and transparency of prescription drug costs, you can better implement policies and measures that increase competition, improve prescription drug affordability and access for the American people.

read more

Comments on prescription drug limitations in proposed Oregon Medicaid waiver

Jan 7, 2022

The HIV+Hepatitis Policy Institute write[s] to express our strong opposition to the proposed limits to the prescription drug formulary that have been included as part of Oregon’s 1115 Medicaid Demonstration Waiver. The stated goal of the waiver is to promote greater equity; however, not only do we believe what Oregon is proposing is not legal, but it will have the opposite effect of promoting equity. We urge you to not include these proposals in your waiver submission.

read more

Comments on the USPSTF draft research plan “Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis”

Dec 6, 2021

We urge the USPSTF to consider the following two recommendations as it finalizes its plan “Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis”: research should explicitly evaluate and describe the ancillary services that are integral to the PrEP intervention and the USPSTF should adopt a more nimble and timely review of the PrEP recommendation as new products see clinical trial success.

read more

Letter in support of the “PrEP Assistance Program Act”

Nov 23, 2021

PrEP is a critical component to ending the HIV epidemic; however, its uptake has been limited, particularly in communities most at risk of HIV, including Black and Latino gay men and Black women. While there are established government programs that are funded for the treatment of HIV, there is no comprehensive nationwide program dedicated for the provision of PrEP. The “PrEP Assistance Program Act” would help fill that void by providing grants to states, community-based organizations, community health centers, and others to establish and support PrEP programs.

read more

Comments on draft hepatitis federal implementation plan

Nov 19, 2021

We cannot achieve the goal of ending hepatitis without increased funding for the key elements of the strategy, including testing, treating, and vaccination. Increasing resources for hepatitis elimination must be our first priority. While this draft hepatitis federal implementation plan was drafted with current resources in mind, there are areas where we would suggest some strengthening.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest